Suppr超能文献

更新:2019 年 10 月美国与电子烟或蒸气相关的肺损伤爆发中患者的特征。

Update: Characteristics of Patients in a National Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injuries - United States, October 2019.

出版信息

MMWR Morb Mortal Wkly Rep. 2019 Nov 1;68(43):985-989. doi: 10.15585/mmwr.mm6843e1.

Abstract

CDC, the Food and Drug Administration, state and local health departments, and other public health and clinical stakeholders are investigating a national outbreak of electronic-cigarette (e-cigarette), or vaping, product use-associated lung injury (EVALI) (1). As of October 22, 2019, 49 states, the District of Columbia (DC), and the U.S. Virgin Islands have reported 1,604 cases of EVALI to CDC, including 34 (2.1%) EVALI-associated deaths in 24 states. Based on data collected as of October 15, 2019, this report updates data on patient characteristics and substances used in e-cigarette, or vaping, products (2) and describes characteristics of EVALI-associated deaths. The median age of EVALI patients who survived was 23 years, and the median age of EVALI patients who died was 45 years. Among 867 (54%) EVALI patients with available data on use of specific e-cigarette, or vaping, products in the 3 months preceding symptom onset, 86% reported any use of tetrahydrocannabinol (THC)-containing products, 64% reported any use of nicotine-containing products, and 52% reported use of both. Exclusive use of THC-containing products was reported by 34% of patients and exclusive use of nicotine-containing products by 11%, and for 2% of patients, no use of either THC- or nicotine-containing products was reported. Among 19 EVALI patients who died and for whom substance use data were available, 84% reported any use of THC-containing products, including 63% who reported exclusive use of THC-containing products; 37% reported any use of nicotine-containing products, including 16% who reported exclusive use of nicotine-containing products. To date, no single compound or ingredient used in e-cigarette, or vaping, products has emerged as the cause of EVALI, and there might be more than one cause. Because most patients reported using THC-containing products before symptom onset, CDC recommends that persons should not use e-cigarette, or vaping, products that contain THC. In addition, because the specific compound or ingredient causing lung injury is not yet known, and while the investigation continues, persons should consider refraining from the use of all e-cigarette, or vaping, products.

摘要

疾病预防控制中心、美国食品和药物管理局、州和地方卫生部门以及其他公共卫生和临床利益攸关方正在调查一起与电子烟或蒸气烟产品使用相关的肺损伤(EVALI)的全国性疫情(1)。截至 2019 年 10 月 22 日,49 个州、哥伦比亚特区和美属维尔京群岛已向疾病预防控制中心报告了 1604 例 EVALI 病例,其中 24 个州有 34 例(2.1%)与 EVALI 相关的死亡。基于截至 2019 年 10 月 15 日的数据,本报告更新了患者特征和电子烟或蒸气烟产品中使用的物质的数据(2),并描述了与 EVALI 相关的死亡特征。幸存的 EVALI 患者的中位年龄为 23 岁,死亡的 EVALI 患者的中位年龄为 45 岁。在 867 名(54%)可提供症状发作前 3 个月内特定电子烟或蒸气烟产品使用情况数据的 EVALI 患者中,86%报告使用过含有四氢大麻酚(THC)的产品,64%报告使用过含有尼古丁的产品,52%报告同时使用过这两种产品。34%的患者报告独家使用含有 THC 的产品,11%的患者报告独家使用含有尼古丁的产品,2%的患者报告两种产品均未使用。在 19 名死亡的 EVALI 患者中,有可获得物质使用数据的患者,84%报告使用过含有 THC 的产品,包括 63%报告独家使用含有 THC 的产品;37%报告使用过含有尼古丁的产品,包括 16%报告独家使用含有尼古丁的产品。迄今为止,在电子烟或蒸气烟产品中使用的任何单一化合物或成分都没有成为 EVALI 的原因,而且可能有不止一个原因。由于大多数患者在出现症状前报告使用过含有 THC 的产品,疾病预防控制中心建议人们不应使用含有 THC 的电子烟或蒸气烟产品。此外,由于导致肺损伤的特定化合物或成分尚未确定,并且在调查继续进行的同时,人们应考虑避免使用所有电子烟或蒸气烟产品。

相似文献

引用本文的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验